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Introduction
Acute gastroesophageal variceal bleeding is a severe
complication in patients with liver cirrhosis and portal
hypertension.1 Arginine vasopressin (AVP) has been
used to treat esophageal variceal bleeding for decades,
and clinical trials revealed that about 50% of the
bleeding episodes could be controlled,2–4 though the
vascular hyporesponsiveness to AVP during acute hem-
orrhage compromises its hemostatic effect.5,6 AVP is a
strong vasoconstrictor capable of inducing splanchnic
vasoconstriction, followed by decreased portal venous
blood flow and portal pressure.7 In addition, lower
azygos venous blood flow and intravariceal pressure
in cirrhotic patients were found after AVP administra-
tion,8,9 suggesting an effect of AVP on portal-systemic
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collaterals. In our previous studies, a direct vasocon-
strictive effect of AVP was demonstrated on the portal-
systemic collaterals of portal-hypertensive and cirrhotic
rats.10,11 Therefore, AVP-induced collateral vasocon-
striction may further contribute to the control of
variceal hemorrhage.
Thalidomide (α-N-phthalimidoglutarimide), a deriv-
ative of glutamic acid, has been incriminated for its
teratogenic effect in the past.12 Recently, it was reported
to be helpful in patients with diverse immunologic or
inflammatory disorders.13,14 It suppresses tumor necro-
sis factor (TNF)-α production by accelerating the
degradation of TNF-α mRNA and vascular endothelial
growth factor (VEGF) related angiogenesis.13–16 In
the portal hypertensive state, chronic administration
of thalidomide reduces TNF-α and nitric oxide (NO)
production as well as ameliorates the portal pressure
and hyperdynamic circulation in partially portal vein-
ligated (PVL) rats.17 However, whether or not thalido-
mide enhances collateral vascular responsiveness to AVP
is unknown.
In this study, the effects of acute and chronic
thalidomide administration on AVP-induced vasocon-
striction were investigated in cirrhotic rats. The plasma
levels and expressions of VEGF and TNF-α mRNA in
the collateral vessels were also evaluated.
Methods
Animal model
Male Sprague-Dawley rats weighing 240–270 g at the
time of surgery were used for experiments. The rats
were housed in a plastic cage and allowed free access
to food and water. All rats were fasted for 12 hours
before the operation. Rats with secondary biliary 
cirrhosis were induced by common bile duct ligation
with formalin infusion (CBDL).18 Under ketamine
anesthesia (100 mg/kg, intramuscularly), the common
bile duct was exposed through a midline abdominal
incision. A PE-10 catheter was used to catheterize the
common bile duct, and the duct was then doubly li-
gated with 3-0 silk. The first ligature was made below
the junction of the hepatic ducts and the second liga-
ture above the entrance of the pancreatic duct. Then,
10% formalin (∼100 μL/100 g) was slowly injected in
the biliary tree to prevent the subsequent dilatation of
the ligated residual bile duct. The PE-10 catheter was
removed and the ligatures tightened, followed by sec-
tion of the common bile duct between the ligatures.
The incision was then closed and the animal allowed
to recover. According to the literature, a high yield of
secondary biliary cirrhosis was noted 5 weeks after the
ligation.18–20 To avoid coagulation defects, CBDL
rats received weekly vitamin K injection (50 μg/kg
intramuscularly). The perfusion studies were performed
in overnight-fasted rats 6 weeks after the operation
under anesthesia by ketamine (100 mg/kg body weight
intramuscularly). The body weights of rats were mea-
sured on the day of perfusion studies. All animals
received humane care according to the criteria out-
lined in the Guide for the Care and Use of Laboratory
Animals prepared by the National Academy of
Sciences and published by the National Institutes of
Health (NIH publication no. 86-23, revised 1985).
This study was approved by Taipei Veterans General
Hospital’s Animal Committee.
Experimental design
Two groups of CBDL rats received either thalido-
mide (50 mg/kg/day orally; kindly provided by TTY
Biopharm Co., Ltd., Taipei, Taiwan) or distilled water
(control) from the 35th to 42nd day after ligation. On
the 43rd day after ligation, rats were anesthesized with
ketamine hydrochloride (100 mg/kg, intramuscularly)
and the body weight, mean arterial pressure, portal
pressure, and heart rate were measured.
Two series of experiments with the in situ collat-
eral vascular perfusion model were performed. In the
first series (thalidomide group, n = 10; control group,
n = 10), cumulative concentration-response curves of
collateral vessels were determined by graded final con-
centrations of AVP in escalation with a constant flow
rate (12 mL/min). The final concentrations in the
perfusate were from 10–10 M to 3 × 10–7 M of AVP.
Each new concentration was allowed to stabilize for 
3 minutes before the next higher concentration was
added. The plasma levels of VEGF and TNF-α were
determined in the thalidomide-treated and control
groups. In addition, the left adrenal veins and the
major collateral vessels of cirrhotic rats were obtained
for testing mRNA expression of VEGF and TNF-α.
In the second series, 10–5 M thalidomide or vehicle
(Krebs solution) was added into the perfusate of col-
lateral perfusion study (thalidomide group, n = 6; con-
trol group, n = 7) in CBDL cirrhotic rats to evaluate
the direct vascular effect of thalidomide in cirrhotic
rats. The cumulative concentration-response curves of
both groups were obtained.
Systemic and portal hemodynamic
measurements
The right internal carotid artery was cannulated with 
a polyethylene PE-50 catheter connected to a Spectra-
med DTX transducer, and permanent recordings of
mean arterial pressure was made on a multichannel
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recorder (model RS 3400; Gould Inc., Cupertino, CA,
USA). The heart rate was calculated from the record-
ings. The abdominal cavity was entered through a mid-
line incision, and the distal mesenteric vein was exposed
and Cannulated with a saline-filled 18-gauge Teflon
cannula and fixed with cyanoacrylate glue. This cannula
was connected with a PE-50 tubing to a Spectramed
DTX transducer. The abdomen was then closed and the
portal pressure recorded on a multichannel recorder.21
In situ perfusion preparation for 
portal-systemic collaterals
The in situ perfusion system was performed as described
in previous reports.10,11,22 Both jugular veins were
cannulated with 16-gauge Teflon cannulas to ensure an
adequate outflow without any resistance even at high
flow rates. Heparin (200 μ/100 g body weight) was
injected through one of the cannulas. The abdomen
was then opened and an 18-gauge Teflon cannula
inserted in the distal mesenteric vein was used as the
perfusate inlet. To exclude the liver from perfusion,
the second loose ligature around the portal vein was
tied. The animal was transferred into a warm chamber
(37 ± 0.5°C). The temperature around the perfusion
area was continuously monitored with a thermometer
placed inside the mesentery and was maintained at
approximately 37 ± 0.5°C with a thermostatic pad and
temperature-controlled infrared lamp. An open-circuit
perfusion was then started with Krebs solution (com-
position in mM: NaCl, 118; KCl, 4.7; KH2PO4, 1.2;
MgSO4, 1.2; CaCl2, 2.5; NaHCO3, 25; dextrose 11.0;
pH 7.4; 37 ± 0.5°C) via the mesenteric cannula by 
a roller pump (model 505S; Watson-Marlow Ltd.,
Falmouth, Cornwall, UK). The perfusate was equili-
brated with carbogen gas (95% O2–5% CO2) by a silas-
tic membrane lung.23 Both the jugular vein cannulas
were simultaneously opened to allow a complete wash-
out of the blood. Pneumothorax was created by open-
ing slits through the diaphragm to increase resistance
in pulmonary arteries and to prevent the perfusate
from entering the left heart chambers. The portal-
systemic collaterals were then perfused with oxygenated 
(95% O2–5% CO2) Krebs solution containing 3%
wt/vol albumin (factor V bovine serum albumin;
Sigma, St Louis, MO, USA). The effluent of the per-
fusion was collected in a reservoir and was not recir-
culated. To continuously monitor and record the
pressure in the portal-systemic collaterals, a Spectramed
DTX transducer attached to the Gould model RS
3400 recorder was connected to a side arm placed
just proximal to the perfusion cannula, with the zero
placed at the level of the right atrium. Because the
temperature and pressure of the system stabilized
within 20 minutes, all the experiments were performed
25 minutes after starting perfusion at a constant rate
of 12 mL/min.11 After the stabilization period, the
perfusion flow rate was kept constant (12 mL/min) in
determining the cumulative concentration-response
curves.
Cumulative concentration-response curve study
In the series one study, the cumulative concentration-
response curves of collateral vessels were determined
by using final concentrations of 10–10, 10–9, 3 × 10–9,
10–8, 3 × 10–8, 10–7 and 3 × 10–7 M of vasopressin in
the perfusate. The final concentrations were success-
fully reached by carefully adding calculated amounts
of vasopressin. Each new concentration was allowed
to stabilize for 3 minutes before the next higher con-
centration was added. Only 1 concentration-response
curve was performed in each preparation. After testing
experimental agents, the contracting capability of the
collateral vessels was challenged with a 125 mM KCl
solution at the end of the experiments. In the series
two study, the collateral vessels were preincubated
with thalidomide (10–5 M) to test its direct effect on
the collateral responsiveness to AVP. The cumulative
concentration-response curves of collateral vessels
were also determined by using final concentrations of
10–10, 10–9, 3 × 10–9, 10–8, 3 × 10–8 and 10–7 M of vaso-
pressin in the perfusate.
Determination of plasma TNF-a levels
The plasma samples were centrifuged at 3,000 rpm
for 10 minutes at 4°C and stored at –80°C until tested.
Plasma TNF-α levels were measured with a commer-
cially available solid-phase sandwich enzyme-linked
immunosorbent assay (rat TNF-α kits; R&D Systems
Inc., Minneapolis, MN, USA) according to the pro-
tocol supplied by the manufacturer. The standards and
samples were incubated with a TNF-α antibody-coated
96-well microtiter plate. The wells were washed with
buffer and then incubated with anti-TNF-α antibody
conjugated to horseradish peroxidase for 2 hours.
This was washed away, and color was developed in the
presence of tetramethyl benzidine chromogen sub-
strate. The intensity of the color was measured in a Bio-
kinetics Reader (Bio-Tek Instruments Inc., Winooski,
VT, USA) by reading the absorbance at 450 nm with
a correction wavelength of 570 nm. We compared the
samples against the standard curve to determine the
amount of TNF-α present. All samples were run in
duplicate. The lower limit of sensitivity for TNF-α
by this assay was 5 pg/mL. The intraassay and inter-
assay coefficients of variation were 5.1% and 9.7%,
respectively.
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Determination of plasma VEGF levels
The plasma levels of VEGF were measured using com-
mercially available enzyme-linked immunoabsorbent
assay kits (R&D Systems Inc.) according to the manu-
facturer’s instructions. Briefly, standards and samples
were pipetted into the wells containing a monoclonal
antibody specific for VEGF. After washing, an enzyme-
linked polyclonal antibody specific for VEGF was added
to the wells. Then, a substrate solution was added to
the wells and the color development in proportion to
the amount of VEGF bound was stopped with a stop
solution. Standard curves were constructed using serial
dilutions of recombinant VEGF. The intensity of the
color was measured to the absorbance of 450–600 nm
with a Bio-kinetics Reader (Bio-Tek Instruments Inc.).
The intra- and interassay variations of these assays were
less than 10%.
Expressions of VEGF and TNF-a mRNA in the
left adrenal veins of CBDL rats
The left adrenal veins of chronic thalidomide or distilled
water-treated cirrhotic rats were obtained. Total RNA
was extracted from the vessel with an RNeasy Mini
Kit (Qiagen GmbH, Hilden, Germany) according to
the manufacturer’s instructions.24,25 Reverse transcrip-
tion of 0.2 μg of RNA using ImProm-II™ Reverse
Transcriptase (Promega, Madison, WI, USA) was 
carried out in a total volume of 20 μL according to the
following protocol: 4 μL of RNA (0.2 μg) and 1 μL of
oligo dT (0.5 μg) were incubated at 70°C for 5 minutes
and then chilled immediately at 4°C for 5 minutes. The
reacting mixture was incubated with 15 μL of reverse
transcriptase mix (RNase-free water 6 μL, ImProm-II™
5X reaction buffer 4 μL, MgCl2 3 μL, dNTP mix
(10 μM each dNTP) 1 μL, ImProm-II™ reverse tran-
scriptase 1 μL) at 42°C for 60 minutes. The resulting
cDNA samples were frozen at this stage until poly-
merase chain reaction (PCR).
PCR was performed using primers specific to VEGF
isoform (forward 5-CCT CCG AAA CCA TGA ACT
TTC TGC TC-3 and reverse 5-CAG CCT GGC TCA
CCG CCT TGG CTT-3; annealing temperature 60°C)
and TNF-α (forward 5-CTC AAA GAC AAC CAA
CTG GTG GTA-3 and reverse 5-ACA GAG CAA
TGA CTC CAA AGT AGA CC-3; annealing tempera-
ture 62°C). A constitutively expressed gene, β-actin, was
used as internal control, and the primers for β-actin were
5-TTGTAACCAACTGGGACGATATGG-3 (sense)
and 5-GATCTTGATCTTCATGGTGCTAGG-3 (an-
tisense), respectively. The primers for VEGF, TNF-α and
β-actin were designed to allow amplification of 593, 343
and 764 base-pair fragments, respectively. A negative
control of the reaction was included in each set of the
experiments. The tubes were placed in the thermo-
cycler (Biometra® T Gradient Thermocycler; Biometra
GmbH, Göttingen, Germany) at 95°C for 5 minutes
for initial denaturation, followed by 35 cycles of the fol-
lowing sequential steps: 30 seconds at 94°C (denatur-
ation) and 45 seconds at 72°C (extension). The final
extension was performed at 72°C for 10 minutes: 10 μL
of the PCR-amplified mixture was subjected to electro-
phoresis on a 2% agarose gel, and cDNA was visualized
by ethidium bromide staining. Location of the predicted
PCR products (base pairs) was confirmed by using a
100-base-pair ladder (Gibco BRL, Gaithersburg, MD,
USA) as a standard size marker. The gel was then pho-
tographed, and the PCR products were quantified by
a digitalizing software (Kodak Digital Science™ ID
Image Analysis Software, Eastman Kodak Comp., Roch-
ester, NY, USA). The intensities of the VEGF and TNF-
α signals were standardized against that of β-actin from
the same RNA sample and expressed as VEGF/β-actin
and TNF-α/β-actin ratio for comparison.
Drugs
Thalidomide was kindly provided by TTY Biopharm
Co., Ltd., Taipei, Taiwan. AVP and the reagents for
preparing Krebs solution were purchased from 
Sigma (Sigma Chemical Co., St Louis, MO, USA).
All the solutions were freshly prepared on the days of
experiment.
Data analysis
All results are expressed as mean ± standard error of
the mean. The changes in perfusion pressure (mmHg)
over baseline were calculated for each concentration
in each preparation. The concentration of vasopressin
exhibiting 50% of the maximal response (EC50) in
each preparation was calculated from sigmoid logistic
curves and expressed as negative log molar (–log M).
Statistical analyses were performed using an unpaired
Student’s t test. Results were considered statistically
significant at a 2-tailed p value of less than 0.05.
Results
Hemodynamic effects and plasma VEGF and
TNF-a levels after thalidomide treatment
Table 1 shows the body weights, baseline hemodynamic
parameters, plasma VEGF and TNF-α levels of the
chronic thalidomide and distilled water-treated (con-
trol) CBDL rats. The mean arterial pressure, heart rates,
portal pressure and baseline perfusion pressure were
similar between the 2 groups. The plasma levels of
VEGF were significantly decreased after thalidomide
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treatment (thalidomide vs. control: 5.0 ± 1.4 pg/mL
vs. 15.5 ± 2.1 pg/mL; p < 0.001). There was also a
trend of lower plasma TNF-α levels in the thalidomide-
treated group. It, however, did not reach statistical sig-
nificance (thalidomide vs. control: 16.4±1.9 pg/mL vs.
20.1 ± 4.0 pg/mL; p = 0.416).
Collateral vascular responsiveness to AVP in
chronic thalidomide and distilled 
water-treated CBDL rats
Figure 1 depicts the concentration-response curves ob-
tained at a constant perfusion flow rate by the cumula-
tive addition of AVP into the perfusate for the 2 groups.
The maximal perfusion pressure change occurred at the
concentration of 10–8 M, and that of the thalidomide
group was significantly higher compared with that of the
control group (18.9±2.4 mmHg vs. 12.8±1.3 mmHg;
p = 0.041). There was no significant difference in EC50
between the 2 groups (thalidomide vs. control (log-
EC50): –7.69 ± 1.44 vs. –8.90 ± 0.18; p = 0.470).
Collateral vascular response to AVP with or
without thalidomide preincubation in 
CBDL rats
Table 2 shows the baseline hemodynamic parameters
and body weights of the 2 groups of CBDL rats with
or without thalidomide preincubation in the perfusate.
The body weights, mean arterial pressures, heart rates,
portal pressure and baseline perfusion pressures were
similar between these 2 groups. Figure 2 shows no
significant perfusion pressure changes at different con-
centrations of these 2 groups (p > 0.05).
Expressions of VEGF and TNF-a mRNA in the
left adrenal veins of thalidomide-treated and
control CBDL rats
The mRNA expressions of VEGF were not significantly
decreased in the left adrenal veins of the thalidomide-
treated group as compared with the control group
(VEGF/β-actin of thalidomide group vs. control
group: 0.39 ± 0.05 vs. 0.42 ± 0.05; p = 0.65) (Figure 3).
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Table 1. Body weights, plasma levels of TNF-α, VEGF and 
hemodynamic parameters in chronic thalidomide-treated 
and control common bile duct-ligated rats
Thalidomide (n = 10) Control (n = 10)
Body weight (g) 359 ± 12 379 ± 15
MAP (mmHg) 99 ± 4 97 ± 6
HR (beats/min) 288 ± 17 292 ± 17
PP (mmHg) 16.8 ± 0.7 17.6 ± 1.1
Baseline PP (mmHg) 16.9 ± 0.8 17.7 ± 1.0
TNF-α (pg/mL) 16.4 ± 1.9 20.1 ± 4.0
VEGF (pg/mL) 5.0 ± 1.4 15.5 ± 2.1*
*p < 0.001. TNF-a = tumor necrosis factor-a; VEGF = vascular endothelial
growth factor; MAP = mean arterial pressure; HR = heart rate; PP = portal
pressure; baseline PP = baseline perfusion pressure.
Table 2. Body weights and hemodynamic parameters in common
bile duct-ligated rats with or without thalidomide preincubation in
perfusion study
Thalidomide (n = 6) Control (n = 7)
Body weight (g) 325 ± 32 318 ± 10
MAP (mmHg) 92 ± 9 101 ± 40
HR (beats/min) 259 ± 21 293 ± 12
PP (mmHg) 17.2 ± 2.1 17.6 ± 1.3
Baseline PP (mmHg) 18.1 ± 1.7 18.0 ± 1.4
MAP = mean arterial pressure; HR = heart rate; PP = portal pressure; base-
line PP = baseline perfusion pressure.
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Figure 1. Concentration-response curves to arginine vasopressin
(AVP) in portal-systemic collateral vascular beds of thalidomide and
distilled-water (control)-treated common bile duct-ligated rats.
−10
AVP (log M)
−8−9 −7
0
3
Pe
rf
us
io
n 
pr
es
su
re
 c
ha
ng
e 
(Δ
m
m
H
g)
6
9
12 Thalidomide
Control
p > 0.05
Figure 2. Concentration-response curves to arginine vasopressin
(AVP) in portal-systemic collateral vascular beds of common bile
duct-ligated rats preincubated with thalidomide or vehicle (Krebs
solution).
There were also no significant changes in TNF-α
mRNA expression (TNF-α/β-actin: 1.15 ± 0.18 vs.
1.27 ± 0.19; p = 0.66) in the left adrenal veins between
the 2 groups (Figure 3).
Discussion
In a previous study, Lopez-Talavera et al found that
thalidomide elevated mean arterial pressure and
decreased portal pressure in partially PVL rats.17 The
alleviated hemodynamic derangements were ascribed
to TNF-α synthesis inhibition by thalidomide. However,
in our study, mean arterial pressure and heart rate were
not significantly different between the thalidomide-
treated and control groups in CBDL-induced cirrhotic
rats. The plasma TNF-α levels were also decreased after
thalidomide treatment in our study but did not reach
statistical significance as compared with the control
group. Thalidomide has been found to inhibit TNF-α
through enhancing its mRNA degradation and has a
marked regulatory influence on the TNF-α protein.15,26
Recently, it has been reported that multiple pathways
are involved in the thalidomide action, including inhi-
bition of nuclear κB activity through suppression of IκB
kinase activity and suppression of TNF-α-dependent
Kupffer cell sensitization.27,28 Elevated blood levels of
TNF-α have been demonstrated in patients and animals
with chronic liver disease and cirrhosis.29,30 TNF-α
participates in the development of the hyperdynamic
circulatory state of portal hypertension mainly through
an increased release of NO.17,31,32 In addition, the
decreased vascular tone and vasodilation by TNF-α
may also be mediated via prostacyclin,32 calcitonin-gene
related peptide33 or activation of potassium channels
in smooth muscle.34 Nevertheless, in another study of
20 abstinent patients with stable alcoholic cirrhosis and
esophageal varices,35 oral thalidomide 200 mg/day for
2 weeks did not alter systemic hemodynamic parameters
and plasma levels of TNF-α. In fact, in ex vivo experi-
ments, individuals with portal hypertension treated
by thalidomide showed potent inhibition of both
basal and lipopolysaccharide-stimulated TNF-α pro-
duction in peripheral blood monocytes in the absence
of plasma TNF-α level changes.35 Since plasma levels
of TNF-α show wide variability with studied animals
and are influenced by various hepatic injuries caused
by CBDL, they may not be a reliable marker to test the
efficacy of the inhibitory activity of thalidomide. Though
the actual reason for discrepant results between these
studies is unknown, different experimental models and
dosages may also play important roles.
In the present study, portal pressure was not altered
by thalidomide treatment. In the study led by Muñoz
in portal-hypertensive rats,32 portal pressure was
unchanged after short- and long-term TNF-α inhibi-
tion, which is in contrast to the results of Lopez-
Talavera et al’s study.31 They postulated that lack of
influence on portal pressure might be associated with
a decrease in portal venous inflow and a concomitant
increase in portal-collateral resistance.32 In addition to
suppressing TNF-α, chronic thalidomide treatment
obviously decreased plasma levels of VEGF. Fernandez
et al demonstrated that anti-VEGF receptor-2 mono-
clonal antibody prevented collateral vessel formation
without any significant effect on portal pressure in
portal hypertensive mice.36 They suggest that it was a
reduction of the splanchnic blood flow and portal
venous inflow due to decreased collateral angiogene-
sis by inhibition of VEGF. Chronic thalidomide treat-
ment in cirrhotic rats had similar effects in decreasing
plasma levels of VEGF without change of portal pres-
sure in the current study. The more likely explanation
is its potent effect in suppression of VEGF and decrease
in portal venous inflow, which may partially account
for the unchanged portal pressure in the thalidomide-
treated cirrhotic rats.
In our study, long-term thalidomide administration
improved vascular responsiveness to AVP in portal
systemic collaterals at the concentration of 10–8 M in
cirrhotic rats. It has been found that TNF-α plays a
role in the mediation of vascular hyporesponsiveness
in the mesenteric vessels of cirrhotic rats,37 the aortic
ring in rats with septic shock,38 and persistent vasodi-
latation in the small intestinal microcirculation of rats
with sepsis.39 TNF-α might cause vasodilation through
both prostaglandin and NO pathways, with the NO-
dependent mechanism being the dominant one.40,41
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Figure 3. Representative diagram of vascular endothelial growth
factor (VEGF) and tumor necrosis factor (TNF)-α mRNA expressions
in the left adrenal veins of common bile duct-ligated (CBDL) rats
after chronic thalidomide and distilled water treatment.
The mechanism by which thalidomide treatment
improves collateral vascular responsiveness to AVP may
partially come from inhibition of TNF-α, though it
did not reach statistical significance. However, the
marked suppression of VEGF in chronic thalidomide-
treated cirrhotic rats may be another important factor
that influences vascular reactivity. VEGF is a potent
activator of NO-dependent vasodilation that stimu-
lates NO production by endothelial NO synthase and
increases vascular permeability, and subsequently
induces the migration and proliferation of endothelial
cells, leading to expansion of pre-existing collateral
vessels.42 Chronic thalidomide treatment decreases
plasma levels of VEGF, which may attenuate the pro-
duction of NO, and then increases collateral vascular
responsiveness to AVP in cirrhotic rats. Apart from
suppression of VEGF, thalidomide and its analogs
have also been demonstrated to inhibit expression of
cyclooxygenase-2 from stimulated human peripheral
blood monocytes.43 In our study, thalidomide treat-
ment did not elicit changes in EC50 values, suggest-
ing that the receptor-mediated vasoconstriction effect
is not influenced by thalidomide and the enhanced
collateral vascular reactivity to AVP may be directed at
the post-receptor level.
Although chronic thalidomide treatment produced
a significant reduction in plasma VEGF levels and 
relatively lower TNF-α levels, the VEGF and TNF-α
mRNA expressions of the left adrenal vein were not
significantly altered after treatment. It has been shown
that expressions of VEGF are upregulated in the jejunal
mucosa microvasculature but not in the mesenteric
vessels 24 hours after PVL.44 However, Geerts et al
demonstrated overexpression of VEGF in the mesen-
tery microvasculature of portal hypertensive and cir-
rhotic rats.45 The significant decrease in plasma VEGF
levels without inhibition of VEGF mRNA expression
in the left adrenal veins might be explained by the fact
that thalidomide inhibits plasma VEGF levels via sys-
temic inhibition of VEGF production with discrepant
expressions of VEGF mRNA in different vascular terri-
tories. Another possible explanation is that thalidomide
inhibits some kind of protease, such as eukaryotic initi-
ation factor 4E (eIF-4E), without alteration in mRNA
expression. eIF-4E is a crucial protease in VEGF pro-
duction. Previous studies have demonstrated that
enhanced VEGF expression is achieved through
translational regulation rather than transcriptional
regulation in cells with overexpression of eIF-4E.46
VEGF is a glycoprotein that induces endothelial 
proliferation, angiogenesis and capillary hyperperme-
abiliy.47 Fernandez et al demonstrated that the for-
mation of portal-systemic circulation might be due to
angiogenesis driven by VEGF and modulated by
VEGF receptor-2.36,48 VEGF plays a crucial role in
the portal hypertension-related collateral vessel for-
mation that includes neoangiogenesis and reopening
of pre-existing vessels. Thalidomide has been shown
to inhibit the expression of VEGF, which is believed to
be the mechanism for the attenuation of angiogenesis
by thalidomide.49
To our knowledge, this is the first study to demon-
strate that thalidomide can increase vascular reactivity
to AVP in the portal-systemic collaterals of cirrhotic
rats, partly related to decreased plasma VEGF levels.
These findings suggest that the improved responsive-
ness to AVP occurs, at least in part, through VEGF
downregulation after thalidomide administration in
CBDL cirrhotic rats. The enhanced vasoconstrictive
activities of AVP may implicate the synergistic effect to
control acute gastroesophageal variceal bleeding. How-
ever, we should be cautious in extrapolating the results
from animal models to humans and await further
studies for elucidation.
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